TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04590274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamins and Minerals
Description: elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin
Study: NCT00383786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK1 Antagoist (GR205171)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Trauma Script)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Trauma Script)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Verbal Threat)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Verbal Threat)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Fear Conditioning)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Fear Conditioning)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Affective Modulation)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Affective Modulation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychophysiology (Heart rate variability)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Psychophysiology (Heart rate variability)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lumbar Puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-hour plasma sampling

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 24-hour plasma sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Study: NCT03863795

Intervention type: OTHER
Intervention: Survey Administration
Description: Respond to SurveyGizmo survey online
Study: NCT02299596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
Study: NCT05904158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin during Standard ACL reconstruction surgery
Description: Plateleth-rich fibrin was obtained from patients own blood (40 cc) and applied to the tunnels which were drilled for ACL graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL reconstruction surgery
Description: This was a control group where patients received Standard ACL reconstruction surgery
Study: NCT01156662

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor resolute or Resolute integrity (Medtronic)
Description: PCI without thrombus aspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)
Description: PCI after thrombus aspiration
Study: NCT00805350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin
Description: one 5 mg tablet once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Eplivanserin one tablet once a day
Study: NCT01095185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simvastatin placebo
Study: NCT01715181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volunteer visits
Description: Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
Study: NCT02657096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybenx treatment (device)
Description: In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hybenx treatment (device)
Description: In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing (SRP)
Description: The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Description: The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
Study: NCT02332538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 532nm-laser photoselective vapo-enucleation of the prostate)
Description: using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of prostate
Description: Holmium-Yag laser enucleation of the prsotate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar TURP
Description: Bipolar transurethral resection of the prostate in saline
Study: NCT03189368

Intervention type: DEVICE
Intervention: Activation of multi-site pacing capability on CRT devices
Description: Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~* Interpolar distance for the first left ventricular pulse \>30mm (i.e. non-sequential poles used)~* Nearly simultaneous (Δt=5msec) second left ventricular pulse and~* Threshold of ≤3.5V@0.5msec
Study: NCT02426580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wechat
Description: The wechat model of dietary education every 1 month by cellphone
Study: NCT02493439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Daily Activities
Study: NCT00825292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polp removal and identification
Description: Identify polyp during colonoscopy then remove polyp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colon polyp removal
Description: identify and remove polyp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETMI colonoscope (ETMI scope is a FDA approved device)
Description: ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETMI colonoscope (ETMI scope is a FDA approved device)
Description: ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
Study: NCT03439280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally.
Study: NCT01097668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATX-MS-1467
Description: Disease specific immune modulating treatment for multiple sclerosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATX-MS-1467
Description: Disease specific immune modulating treatment for multiple sclerosis
Study: NCT02905136

Intervention type: OTHER
Intervention: Fundamental research
Description: serum, whole blood, cerebrospinal fluid
Study: NCT02570932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal Bone Marrow Cell
Description: Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration
Study: NCT02518737

Intervention type: OTHER
Intervention: Meal Test

Intervention type: OTHER
Intervention: Meal Test
Study: NCT02314845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal PEEP
Description: Optimal PEEP determined by EIT during a PEEP titration procedure.
Study: NCT03270436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program
Description: Faith based diabetes curriculum that teaches participants to connect faith and health.
Study: NCT02314845

Intervention type: OTHER
Group type: OTHER
Intervention: Low PEEP
Description: Use of PEEP of 4 cmH2O during intraoperative period
Study: NCT03270436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership for Improving Lifestyle Intervention Diabetes Prevention Program
Description: Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
Study: NCT00575185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valomaciclovir
Description: 4 grams orally of valomaciclovir (2 grams BID) for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets orally twice daily for 21 days.
Study: NCT02516280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoton ™
Description: In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control ice bag
Description: In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
Study: NCT02675946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGX1321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGX1321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGX1321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02730637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early nephrologist consultation
Study: NCT00879866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EMD 521873
Description: After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
Study: NCT02389920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT02675946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT03858049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinone
Description: Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinone
Description: Participants received Crinone 8% (90 milligrams \[mg\] an intravaginal progesterone gel contained in a single use, one piece applicator) once daily in morning from the day of endometrial transformation (Day -5) until ongoing pregnancy was confirmed up to Day 63.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duphaston
Description: Participants received 10 mg of Duphaston tablet orally twice a day from the day of endometrial transformation (Day -5) until ongoign pregnancy was confirmed up to Day 63.
Study: NCT02845297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitadine
Description: Intravenous or subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitadine
Description: Intravenous or subcutaneous
Study: NCT01796340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food cue exposure
Description: Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
Study: NCT03177863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expectancy
Description: Clinical monitoring. See arm description
Study: NCT03770234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transtec 35 µg/hour transdermal patch
Description: Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transtec 35 µg/hour transdermal patch
Description: Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
Study: NCT03245203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FOLFIRI+beacizumab
Description: Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4\~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4\~8 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: total dose of radiotherapy was 40\~50Gy, a subdose of 1.8\~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
Study: NCT04231669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anzansi Family Program
Description: the ANZANSI that combines Family Economic Empowerment (EE) with Multiple Family Groups (MFG). Family EE includes: 1) Workshops on asset building, future planning, and protection from risks; 2) Child Development Account (CDA); and 3) Family income-generating/microenterprise promotion (IGA) component:~MFG a family-centered, group-delivered, evidence-informed intervention designed for children and adolescents whose families struggle with poverty and associated stressors. The MFG is based on building family support through opportunities for parents and children to communicate in a safe setting with other families who have shared experiences, and allow each family to learn from one another. MFG builds protective factors for healthy parent-child relationships while addressing familial, social and community stressors and barriers to adolescent girls' well-being. Both adolecsnt girls and their caregivers will receive the intervention.
Study: NCT03824223

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypoxic challenge test
Description: Physiological response to 15% ambient oxygen monitored.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hypoxic challenge test
Description: Physiological response to 15% ambient oxygen monitored.
Study: NCT01026545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 500 mg once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match 500 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 750 mg once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match 750 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1100 mg once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match 1100 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: Optional cohort with dose not greater than 1100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Optional cohort to match dose not greater than 1100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 750 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match 750 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1100 mg dose once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match 1100 mg dose once daily for 10 days
Study: NCT00966836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-emptive strategy with valganciclovir plus everolimus
Description: Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis with valganciclovir plus mycophenolate
Description: Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis with valganciclovir plus everolimus
Description: Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-emptive mycophenolate
Description: Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
Study: NCT01512485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg
Study: NCT02300792

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: honey
Description: Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: honey
Description: Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: molasses
Description: Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: molasses
Description: Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
Study: NCT01275352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 50 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 50 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02719535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corneal reshaping therapy
Description: Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
Study: NCT02714400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine 50mg before sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One piece of placebo before sleep